Abbott Laboratories gains attention as medical devices, diabetes care, cardiovascular products, and raised guidance ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q2 CY2026, with sales up 13% year on year to $12.59 ...

Abbott’s valuation debate sharpens as legal pressure eases and medical devices, diagnostics, earnings quality, and future cash generation support its outlook.

One of the biggest themes in the healthcare industry right now is the rise of effective new obesity and diabetes medications. Novo Nordisk and Eli Lilly are dominating the space with blockbuster drugs ...

Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.

Abbott Laboratories reported a 4% increase in quarterly sales, totalling $10.4 billion. The company released its latest earnings report Thursday and subsequently revised its full-year financial ...

A recent acquisition is already bearing fruit.